Edition:
United States

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

156.57USD
21 Jun 2018
Change (% chg)

$-1.06 (-0.67%)
Prev Close
$157.63
Open
$157.88
Day's High
$157.88
Day's Low
$155.58
Volume
354,991
Avg. Vol
576,326
52-wk High
$178.17
52-wk Low
$125.50

Latest Key Developments (Source: Significant Developments)

Vertex Pharmaceuticals Inc Reports Qtrly EPS Of $0.81
Thursday, 26 Apr 2018 04:05pm EDT 

April 26 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS.QTRLY EARNINGS PER SHARE $0.81.QTRLY ADJUSTED EARNINGS PER SHARE $0.76.QTRLY TOTAL REVENUES $640.8 MILLION VERSUS $714.7 MILLION.COMPANY REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.65 BILLION TO $2.80 BILLION.Q1 EARNINGS PER SHARE VIEW $0.63, REVENUE VIEW $622.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Vertex Initiates Phase 3 Studies Of Vx-445, Tezacaftor And Ivacaftor
Thursday, 26 Apr 2018 04:01pm EDT 

April 26 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX INITIATES PHASE 3 STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS - FIRST PHASE 3 STUDY WILL EVALUATE ABOUT 360 PEOPLE WITH CF WHO HAVE 1 COPY OF F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION.VERTEX PHARMACEUTICALS INC - SECOND PHASE 3 STUDY WILL EVALUATE APPROXIMATELY 100 PEOPLE WITH CF WHO HAVE TWO COPIES OF F508DEL MUTATION.VERTEX - ANNOUNCES RESULTS FOR VX-561 WHEN DOSED AS PART OF A TRIPLE COMBO REGIMEN IN PHASE 2 STUDIES OF PEOPLE WITH 1 F508DEL MUTATION & 1 MINIMAL FUNCTION MUTATION.VERTEX PHARMACEUTICALS INC - VX-561 WHEN DOESED AS PART OF THE TRIPLE COMBINATION REGIMENS WERE GENERALLY WELL TOLERATED.  Full Article

Q-State Biosciences Says Entered Strategic Collaboration With Vertex Pharmaceuticals
Wednesday, 4 Apr 2018 08:00am EDT 

April 4 (Reuters) - Vertex Pharmaceuticals Inc ::CO'S NOVEL OPTOPATCH PLATFORM.PER TERMS OF DEAL, CO TO RECEIVE UPFRONT & RESEARCH SUPPORT, ELIGIBLE TO RECEIVE RESEARCH, DEVELOPMENT & SALES MILESTONES.STATE WILL ALSO RECEIVE ROYALTIES ON DRUG SALES.CO, VERTEX PHARMACEUTICALS WILL COLLABORATE FOR AT LEAST TWO YEARS.VERTEX IS RESPONSIBLE FOR ALL DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES RESULTING FROM COLLABORATION.  Full Article

Vertex Initiates Late Stage Study Of Treatment Combination For Cystic Fibrosis
Wednesday, 21 Feb 2018 04:01pm EST 

Feb 21 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX INITIATES FIRST PHASE 3 STUDY OF VX-659, TEZACAFTOR AND IVACAFTOR AS A TRIPLE COMBINATION REGIMEN FOR PEOPLE WITH CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS INC - GLOBAL PHASE 3 STUDY TO ENROLL 360 PATIENTS WITH ONE F508DEL MUTATION AND ONE MINIMAL FUNCTION MUTATION.VERTEX - PHASE 3 VX-659 STUDY DESIGNED TO SUPPORT SUBMISSION OF NDA IN U.S. BASED ON 4-WEEK PRIMARY EFFICACY ENDPOINT AND 12-WEEK SAFETY DATA.  Full Article

Vertex Pharma Says Established Wholesale Acquisition Cost Of $292,000 For SYMDEKO In U.S. On Annual Basis
Monday, 12 Feb 2018 05:11pm EST 

Feb 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMA - HAVE ESTABLISHED WHOLESALE ACQUISITION COST FOR SYMDEKO IN UNITED STATES OF $292,000 ON ANNUAL BASIS ($22,400 PER 28-DAY PACK).VERTEX PHARMA SAYS ANTICIPATE FY 2018 TOTAL CF NET PRODUCT REVENUE OF $2.65 BILLION TO $2.80 BILLION FROM KALYDECO, ORKAMBI AND SYMDEKO - SEC FILING.VERTEX PHARMACEUTICALS -REITERATING ‍COMBINED GAAP RESEARCH AND DEVELOPMENT, SALES, GENERAL, ADMINISTRATIVE EXPENSES IN 2018 TO BE IN RANGE OF $1.80 TO $1.95 BILLION.VERTEX PHARMA- ‍ REITERATING COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SALES, GENERAL, AND ADMINISTRATIVE EXPENSES WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION IN 2018​.  Full Article

Vertex Pharma Says FDA Approved SYMDEKO For Treating Underlying Cause Of Cystic Fibrosis
Monday, 12 Feb 2018 04:50pm EST 

Feb 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMACEUTICALS INC - FDA APPROVED SYMDEKO FOR TREATING UNDERLYING CAUSE OF CYSTIC FIBROSIS IN PEOPLE AGES 12 AND OLDER​.VERTEX PHARMACEUTICALS INC - ‍READY TO LAUNCH SYMDEKO AND WILL BEGIN SHIPPING IT TO PHARMACIES IN UNITED STATES THIS WEEK​.  Full Article

Vertex Pharmaceuticals Reports Q4 Shr of $0.39
Wednesday, 31 Jan 2018 04:25pm EST 

Jan 31 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMACEUTICALS - QTRLY EARNINGS PER SHARE $0.39; QTRLY NON-GAAP EARNINGS PER SHARE $0.61; QTRLY TOTAL REVENUES $651.6 MILLION VERSUS $458.7 MILLION.VERTEX PHARMACEUTICALS INC Q4 EARNINGS PER SHARE VIEW $0.53, REVENUE VIEW $594.7 MILLION -- THOMSON REUTERS I/B/E/S.VERTEX PHARMACEUTICALS - QTRLY TOTAL CF NET PRODUCT REVENUES INCREASED 37 PERCENT TO $621.2 MILLION FROM $454 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM ORKAMBI INCREASED 32 PERCENT TO $365.4 MILLION FROM $276.9 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - QTRLY NET PRODUCT REVENUES FROM KALYDECO INCREASED 44 PERCENT TO $255.8 MILLION FROM $177.1 MILLION FOR Q4 2016.VERTEX PHARMACEUTICALS - EXPECTS COMBINED GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE IN 2018 WILL BE IN RANGE OF $1.80 BILLION TO $1.95 BILLION.VERTEX PHARMACEUTICALS - SEES 2018 COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE WILL BE IN RANGE OF $1.50 BILLION TO $1.55 BILLION.VERTEX PHARMACEUTICALS - PLANS TO PROVIDE TOTAL CF PRODUCT REVENUE GUIDANCE FOR FY 2018 UPON ANTICIPATED FDA APPROVAL OF TEZACAFTOR/IVACAFTOR COMBINATION.VERTEX PHARMACEUTICALS - BOARD AUTHORIZED SHARE REPURCHASE PROGRAM OF UP TO $500 MILLION OF COMMON STOCK THROUGH DEC 31, 2019.VERTEX PHARMACEUTICALS - REPURCHASE PROGRAM IS EXPECTED TO BE EXECUTED OVER TWO YEARS.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
Thursday, 7 Dec 2017 08:00am EST 

Dec 7 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS.VERTEX PHARMACEUTICALS - KALYDECO​ ‍STUDY MET PRIMARY SAFETY ENDPOINT, SHOWED IMPROVEMENTS ACROSS MULTIPLE ENDPOINTS.VERTEX PHARMACEUTICALS - ‍ARRIVAL STUDY GENERALLY WELL TOLERATED, SAFETY DATA WERE CONSISTENT WITH THOSE SEEN IN PREVIOUS PHASE 3 STUDIES OF IVACAFTOR​.VERTEX PHARMACEUTICALS INC - ‍VERTEX PLANS TO SUBMIT APPLICATIONS FOR IVACAFTOR TO FDA AND EMA IN Q1 OF 2018​.  Full Article

Vertex reports Q3 non-GAAP earnings per share $0.53
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Vertex Pharmaceuticals Inc :Vertex reports third-quarter 2017 financial results.Q3 non-GAAP earnings per share $0.53.Q3 GAAP loss per share $0.41.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says ‍third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016​.Says ‍increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance​.Vertex Pharmaceuticals Inc qtrly ‍product revenues for ORKAMBI $336 million and $213 million for KALYDECO​.Says ‍reiterated its 2017 combined GAAP and non-GAAP research and development and SG&A expense guidance​.Says ‍now expects total 2017 CF product revenues of $2.10 to $2.15 billion​.Vertex Pharmaceuticals Inc ‍increases FY ORKAMBI revenue guidance to $1.29 to $1.32 billion and KALYDECO revenue guidance to $810 to $830 million​.  Full Article

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.